Skip to content

Diabetic Foot Ulcer Study on Topical Interventions

Randomized, Controlled Study of Nanocrystalline Silver, Manuka Honey and Conventional Dressing in Healing Diabetic Foot Ulcer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02577900
Acronym
DFU
Enrollment
31
Registered
2015-10-16
Start date
2013-02-28
Completion date
2015-08-31
Last updated
2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot

Keywords

foot ulcer and honey and silver

Brief summary

The purpose of this study is to determine whether nanocrystalline silver dressing, manuka honey dressing and conventional dressing are effective in the treatment of diabetic foot ulcer.

Detailed description

Patient flow The target subjects were screened in the orthopedic department of two regional hospitals and one general outpatient clinic (GOPD). Those eligible potential subjects were recruited after they discharged from hospital according to the selection criteria. All the subjects were referred and intervened in an orthopedic nurse clinic a regional hospital. The subjects were randomized into three groups through a fixed block of 10 by online software. A sequence of assignment was generated and put into a sealed envelope by a research assistant. The investigator did not involve in randomization process and allocation sequence. The subjects were enrolled and allocated to different treatment arms according to the allocation sequence. Data collection Outcome assessor blinding was employed in this study. A research assistant was responsible for measuring the wound size and taking clinical photo. In every clinical visit, the research assistant waited outside the clinic until the removal and proper cleansing of the wound by the first author so that she unaware of the topical treatment option. The subjects would be discontinued follow up when the wound was completely healed or till the end of 12-week study period. Intervention All participants attended the nurse clinic for follow-up by the first author (nurse consultant) weekly in the first four week and then biweekly till 12 weeks of follow up period. They were nine clinical attendances totally. At each visit, sharp debridement for the non-viable tissue and stimulation of the vascularity on the avascular tissue were performed if needed by the first author. Then, he applied the topical dressing according to randomization sequence. Statistical analysis All the analysis will be carried out according to the intention-to-treat principle. SPSS Statistics for Mac version 22 (SPSS Inc, Chicago, Illinois) was used for data analysis. Comparison would be made among groups by Fisher's exact test for nominal data and Kruskal-Wallis test for ordinal and scale data. The complete ulcer healing was compared among groups by Kaplan-Meier estimates. General estimating equation (GEE) was used to compare the ulcer size reduction rate, the wound fluid concentration of matrix metalloproteinase -9 (MMP9), tumor necrosis factor alpha (TNF-α) and interleukin-1 alpha (IL-1α) among groups. Statistical significance was set at p \< 0.05 for all tests. Sample size calculation * The probability of non-healing (p1) on nanocrystalline silver (nAg) group = 0.20 * The probability (p2) of non-healing on manuka honey (MH)/conventional group = 0.50 * The alpha (α) value was 0.05 and power (1-β) was 0.8 * Ratio of sample size per group was 1:1 * Therefore, the total sample subjects for 2 groups were 77. Each group needed 39 subjects. For 3 groups, the total numbers of subjects were 117. * From the experience, 10% of patients were loss to follow up. The actual numbers of subjects needs were 129. i.e. 43 subjects per group. Data quality assurance In order to ensure the data quality, a research assistant was assigned to verify the source document and other trial records were accurate, complete, kept up-to-date and maintained. The student investigator trained the research assistant in the data quality assurance process. The student investigator also checked the data entry sheet with raw data every month. The responsibilities of research assistant were listed as follows. * Check the accuracy and completeness on the case screening form and consent form. * Verify the laboratory data in the case record form (CRF) were consistent with the corresponding laboratory result. * Verify the inter-current illness was reported on the CRF. * Verify all withdrawals and dropouts of enrolled subjects from this trial were reported and explained on the CRF. If there was any missing data or data inconsistency, the research assistant was clarified the data with the internal electronic record of the hospital. Handling of missing data The nature of this study was the multiple observations of subjects in regular censored points. Thus, the missing clinical data was handled by the last observation carried forward. For those laboratory data, statistical method of general estimating equation was used for the analysis on the repeated measures among groups. The missing data was under the missing completely at random (MCAR) assumption. Therefore, the laboratory missing data did not need to make estimation in the present study.

Interventions

Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval

DEVICEHoney gel sheet

Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval

DEVICEJelonet

Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval

Sponsors

The Hong Kong Polytechnic University
CollaboratorOTHER
Queen Elizabeth Hospital, Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* History of type 2 diabetes mellitus and * Age 40 or above with foot ulcer and * Ulcer with size equals or larger than 1 cm in diameter and * Ulcer located at or below malleolar region of foot and * Superficial ulcer, ulcer penetrates to tendon or capsule and * Ulcer without infection, mild and moderate infection and * Subject with no foreseeable surgery within 12-week study period

Exclusion criteria

* HbA1c level ≥ 10% or * Severe ischemia with ankle-brachial index (ABI) ≤ 0.4 or * Ulcer deep into bone and joint or * Osteomyelitis or * Severe ulcer infection or * Known allergy to manuka honey/ nanocrystalline silver or * Known case of venous ulcer or varicose vein or * Known case of benign or malignant tumor or * Known to have any auto-immune disease or * A condition requiring medication that affects the immune response or * Participation in other experimental treatment studies or * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Complete Healing of Ulcer During the Observation Period12 weeksThe number of participants have absence of a visible wound achieved by complete epithelialization

Secondary

MeasureTime frame
Change in Ulcer Size12 weeks
the Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4Week 1, Week 4
the Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4Week 1, Week 4
the Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4Week 1, Week 4

Participant flow

Participants by arm

ArmCount
Acticoat Absorbent
Apply Acticoat absorbent onto the ulcer Acticoat absorbent: Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
11
Honey Gel Sheet
Apply Honey gel sheet onto the ulcer Honey gel sheet: Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
10
Jelonet
Apply Jelonet onto the ulcer Jelonet: Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
10
Total31

Baseline characteristics

CharacteristicActicoat AbsorbentHoney Gel SheetJelonetTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
5 Participants3 Participants4 Participants12 Participants
Age, Categorical
Between 18 and 65 years
6 Participants7 Participants6 Participants19 Participants
Age, Continuous63.36 years
STANDARD_DEVIATION 11.31
65.6 years
STANDARD_DEVIATION 11.42
66.1 years
STANDARD_DEVIATION 12.31
64.97 years
STANDARD_DEVIATION 11.34
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
4 Participants6 Participants3 Participants13 Participants
Sex: Female, Male
Male
7 Participants4 Participants7 Participants18 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 110 / 100 / 10
other
Total, other adverse events
0 / 110 / 100 / 10
serious
Total, serious adverse events
0 / 110 / 100 / 10

Outcome results

Primary

Number of Participants With Complete Healing of Ulcer During the Observation Period

The number of participants have absence of a visible wound achieved by complete epithelialization

Time frame: 12 weeks

ArmMeasureValue (NUMBER)
Acticoat AbsorbentNumber of Participants With Complete Healing of Ulcer During the Observation Period9 participants
Honey Gel SheetNumber of Participants With Complete Healing of Ulcer During the Observation Period5 participants
JelonetNumber of Participants With Complete Healing of Ulcer During the Observation Period4 participants
Secondary

Change in Ulcer Size

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
Acticoat AbsorbentChange in Ulcer Size97.45 percentage of ulcer size changesStandard Deviation 5.98
Honey Gel SheetChange in Ulcer Size86.25 percentage of ulcer size changesStandard Deviation 15.98
JelonetChange in Ulcer Size77.51 percentage of ulcer size changesStandard Deviation 26.4
Secondary

the Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4

Time frame: Week 1, Week 4

ArmMeasureGroupValue (MEAN)Dispersion
Acticoat Absorbentthe Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4week 11.13 ng/ mlStandard Deviation 1.17
Acticoat Absorbentthe Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4week 40.57 ng/ mlStandard Deviation 0.96
Honey Gel Sheetthe Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4week 11.93 ng/ mlStandard Deviation 1.32
Honey Gel Sheetthe Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4week 42.08 ng/ mlStandard Deviation 2.28
Jelonetthe Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4week 10.62 ng/ mlStandard Deviation 0.71
Jelonetthe Change in Concentration of Interleukin-1 Alpha (IL-1α) Level Inside Wound Fluid at Week 1 and Week 4week 42.21 ng/ mlStandard Deviation 2.7
Secondary

the Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4

Time frame: Week 1, Week 4

ArmMeasureGroupValue (MEAN)Dispersion
Acticoat Absorbentthe Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4week 13412.38 ng/ mlStandard Deviation 5322.27
Acticoat Absorbentthe Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4week 45720.59 ng/ mlStandard Deviation 10480.71
Honey Gel Sheetthe Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4week 15655.76 ng/ mlStandard Deviation 7163.14
Honey Gel Sheetthe Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4week 417672.54 ng/ mlStandard Deviation 11276.75
Jelonetthe Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4week 15365.84 ng/ mlStandard Deviation 13725.55
Jelonetthe Change in Concentration of Matrix Metalloproteinases-9 (MMP-9) Level Inside Wound Fluid at Week 1 and Week 4week 41987.39 ng/ mlStandard Deviation 2892.48
Secondary

the Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4

Time frame: Week 1, Week 4

ArmMeasureGroupValue (MEAN)Dispersion
Acticoat Absorbentthe Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4week 19.93 ng/ mlStandard Deviation 6.21
Acticoat Absorbentthe Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4week 421.77 ng/ mlStandard Deviation 18.26
Honey Gel Sheetthe Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4week 124.89 ng/ mlStandard Deviation 26.76
Honey Gel Sheetthe Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4week 412.44 ng/ mlStandard Deviation 9.13
Jelonetthe Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4week 19.92 ng/ mlStandard Deviation 8.83
Jelonetthe Change in Concentration of Tumor Necrosis Factor Alpha (TNF-α) Level Inside Wound Fluid at Week 1 and Week 4week 411.03 ng/ mlStandard Deviation 8.51

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026